Biotech Values

[DewDiligence]

OGXI—Anyway, I don’t believe [Teva] would cut it just before the SYNERGY's interim analysis. They would look really stupid if the interim crosses the boundary. If they have any intention to do so, they would wait few more months for the interim and then announce it.

Agreed; moreover, Teva’s impetus to cut development programs has lessened since Teva prevailed in the Copaxone patent case. (Had Teva lost that case, which could still eventually happen on appeal, Teva would surely have responded by cutting development programs broadly and deeply.)